(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 October 2011 (20.10.2011)

PCT

(10) International Publication Number
WO 2011/127567 A1

(51) International Patent Classification:
C07D 495/04 (2006.01) *A61P 27/02* (2006.01)
A61K 31/444 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/CA2011/000394

(22) International Filing Date:
8 April 2011 (08.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/324,803 16 April 2010 (16.04.2010) US

(71) Applicant *(for all designated States except US)*: **METHYLGENE INC.** [CA/CA]; 7210 Frederick-Banting, Montréal, Québec H4S 2A1 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **RAEPPEL, Stéphane** [CA/CA]; 2620 rue de l'Étrier, St. Lazare, Québec J7T 3L8 (CA). **RAEPPEL, Franck** [CA/CA]; 3194 rue Claude Jodoin, Montréal, Québec H1Y 3M2 (CA). **CLARIDGE, Stephen William** [CA/CA]; 443 Notre Dame East, Apt. 2, Montréal, Québec H2Y 1C9 (CA). **ZHAN, Lijie** [CA/CA]; 2540 Boulevard de la Côte Vertu, Montréal, Québec H4R 1P5 (CA). **GAUDETTE, Frédéric** [CA/CA]; 1683 rue Malherbe, Sherbrooke, Québec J1N 0R1 (CA). **MANNION, Michael** [CA/CA]; 74 rue St. Cuthbert, Montréal, Québec H2W 1L5 (CA). **SATO, Norifumi** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **YUKI, Yohei** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **KISHIDA, Masashi** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **VAISBURG, Arkadii** [CA/CA]; 10 Riverwood Grove, Kirkland, Québec H9J 2X2 (CA).

(74) Agent: **BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.**; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

(54) Title: INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY



(II)



(III)

(57) Abstract: Compounds that inhibit protein tyrosine kinase activity are disclosed, preferably of Formulae (II) and (III). In particular, said compounds inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides said compounds, compositions thereof and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.

WO 2011/127567 A1